Resulting directly from the discovery of virus-related antigens, rapid progress has marked the last decade of viral hepatitis research. The hepatitis B virion has been tentatively identified as a DNA virus with an endogenous DNA polymerase, and new serological markers for type B hepatitis have been discovered. Hepatitis A antigen has been identified on a virus-like particle thought to be the hepatitis A virion. Progressively more sophisticated assays for hepatitis antigens and antibodies have been applied to the study of viral hepatitis epidemiology and biochemicalbiophysical characterization of the agents. Most recently, knowledge learned from such studies has been exploited to develop a prototype non-infectious but immunogenic hepatitis B vaccine using hepatitis B surface antigen (HB,Ag) purified in large quantities from chronic HB,Ag carriers. Especially exciting is the prospect, suggested by serological studies of viral hepatitis, that hepatitis viruses besides hepatitis A and B viruses will be identified.
Introduction
Although hepatitis has been recognized clinically for centuries and epidemics of hepatitis have been considered viral in origin for decades, and despite recent advances in tissue culture techniques, hepatitis viruses have not been cultivated in vitro or positively identified. Within the last 6 years, however, virus-like structures associated with type B (Dane, Cameron and Briggs, 1970) and type A (Feinstone, Kapikian and Purcell, 1973) hepatitis have been found, and evidence supporting their aetiological roles is accumulating. Little more than a decade has elapsed since the serendipitous discovery of Australia antigen (Blumberg, Alter and Visnich, 1965) and its ultimate association with type B viral *This work was presented in part at the Congress on Advances in Hepatology, 1976, Boario Terme, Italy, 28 March, 1976.
Correspondence: Dr J. L. Dienstag, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, U.S. A. hepatitis (Prince, 1968; Blumberg et al., 1967 (Bayer, Blumberg and Werner, 1968) , and a 42-nm doubleshelled structure, the Dane particle (Dane et al., 1970) , which is thought to represent the hepatitis B virion (Fig. 1) . The outer coat of the Dane particle measures 7 nm in width and is antigenically identical to the 22-nm spheres and tubules present in abundance and thought to represent excess viral coat material (Table 1) . Residing on each HB,Ag particle or component is a group-reactive determinant, a, and, generally, mutually exclusive allelic subdeterminants d, y (Le Bouvier et al., 1972) , and w, r (Bancroft, Mundon and Russell, 1972) , as well as numerous other recently discovered but less well characterized sub-determinants (Le Bouvier and Williams, 1975) . As a result, four virus-determined major subtypes of HB,Ag are recognized: adw, ayw, adr, and ayr. In infected liver cells, HBsAg reactivity is localized to the cytoplasm (Edgington and Ritt, 1971) , and 22-nm spheres can be detected there by electron microscopy (Huang et al., 1974) . Barker et al., 1974) . Staining infected liver tissue with fluorescein-labelled antibody to HB,Ag (anti-HB,) (Barker et al., 1973) as well as electron microscopic observation (Barker et al., 1973; Huang, 1972) localize HBcAg to the hepatocyte nucleus (Table 1) .
Dane particle DNA and DNA polymerase Among the most exciting recent advances in the study of type B hepatitis are the localization of an HBV-specific DNA-dependent DNA polymerase (Kaplan et al., 1973; ) and a double-stranded circular DNA molecule within the core of the Dane particle . From Dane particles with DNA polymerase activity, double stranded circular DNA molecules have been extracted; their length cornesponds to a molecular weight of 1-6 x 106 daltons which, theoretically, can code for about three average size proteins, and evidence suggests that these DNA molecules serve as the primer-template for synthesis of new DNA by the DNA polymerase (Robinson, Clayton and Greenman, 1974) . Recently, Gerin, Ford and Purcell (1975) and Kaplan et al. (1976) described the existence of two sub-populations of Dane (Krugman et al., 1974;  Kaplan, Gerin and Alter, 1974) ; at approximately the same time, anti-HB, appears and often coincides with biochemical and clinical evidence of acute hepatitis (Hoofnagle et al., 1973;  Hoofnagle, Gerety and Barker, 1975) . Usually not until HB,Ag disappears does anti-HB, appear (Lander et al., 1972) , following which it can be detected by sensitive assays for years after illness. Thus, during acute type B hepatitis, a brief interval may exist between the disappearance of HB,Ag and the appearance of anti-HB, during which anti-HB, is the only indicator of HBV infection (Hoofnagle et al., 1975) (Fig. 2) .
The degree and duration of each of these serological findings may vary among acutely affected individuals, and the course of events differs considerably among chronic HBsAg carriers. Since HBsAg persists in the blood, no anti-HBs is detected.
Furthermore, persistence of elevated DNA polymerase activity and rising titres of anti-HBc (Hoofnagle et al., 1975) The most recently popularized addition to our ever growing awareness of the complexity of HBV is the 'e' antigen system (Magnius and Espmark, 1972a, b America, 59, 849. 1975.) is antigenically distinct from HBsAg of all subtypes.
These antigens (at least two, e1 and e2, have been identified) are found only in serum containing HB,Ag, do not cross-react at all with HB,Ag (Magnius and Espmark, 1972a, b) or HBcAg (Takahashi et al., 1976) , and appear within the first several weeks of clinically recognizable illness (Magnius et al., 1975) (Table 1) . Preliminary reports associate the presence of e antigen in serum with the development and perpetuation of chronic hepatitis or cirrhosis (Nielsen, Dietrichson and Juhl, 1974) , with the presence of Dane particles, DNA polymerase (El Sheikh et al., 1975; Nordenfelt and Kjellen, 1975) and relatively high infectivity of HBsAg serum. Anti-e, on the other hand, appears to correlate with resolution of liver disease, better prognosis, and relatively low infectivity. Although these correlations are not absolute, studies of the properties of e and its epidemiology promise to unravel still more of the mysteries of HBV.
Since, at present, there is no widely available method to abort chronic carriage of HBV, the question of infectivity of chronic carriers has practical significance. Do (Ling and Overby, 1972) . A less costly method, often of comparable sensitivity, immune adherence haemagglutination has been used widely in Japan to screen donor units before transfusion (Mayumi, Okochi and Nishioka, 1971) .
Agar gel diffusion and counter-immunoelectrophoresis (CEP), the earliest tests used to identify HB,Ag are too insensitive to detect anti-HB, in any but the most strongly positive sera. Passive haemagglutination (Vyas and Shulman, 1970) and several modifications of radioimmunoassay, including radioimmunoprecipitation (Lander, Alter and Purcell, 1971) , are very sensitive and are used currently for definitive determinations. Immune adherence haemagglutination, also useful for sensitive, practical anti-HB, testing, is being increasingly accepted (Mayumi et al., 1971 ).
Shortage of HBcAg precludes the commercial availability of assays to detect anti-HBc. The methods used in investigative laboratories, in ascending order of sensitivity, are complement fixation (Hoofnagle et al., 1973) , CEP (Huang and Groh, 1973) , immune adherence haemagglutination (Tsuda et al., 1975) , and radioimmunoassay Moritsugu et al., 1975) .
Epidemiology
Equipped with a vast array of test procedures for hepatitis B antigens and antibodies, investigators have learned much about the transmission of type B hepatitis, as reviewed recently by Mosley (1975) and Szmuness (1975 (Redeker, 1975 (Brzosko et al., 1974) , and hepatic cell carcinoma (Williams, 1975 Courouce-Pauty, Delons and Soulier, 1975; Desmyter et al., 1975; Seeff et al., 1975; Surgenor et al., 1975; Grady and Lee, 1975; Prince et al., 1975; Redeker et al., 1975) , more promising is the progress toward development of an HBV vaccine for active immunization. Unique among modem viral vaccines, an HBV vaccine has been prepared without cultivating HBV in vitro: instead, the 22-nm spherical forms of HB5Ag were purified from the plasma of chronic HBsAg carriers (Purcell and Gerin, 1975; . Separated from Dane particles and tubular forms of HB5Ag,. then inactivated with formalin, the 22-nm particle vaccine has been shown to be immunogenic but non-infectious. In a preliminary study, vaccinated chimpanzees were protected against HBV infection when challenged 24 weeks after vaccination, whereas non-vaccinated chimpanzees developed hepatitis . Another approach to vaccine development, the use of polypeptides derived from HB8Ag, is also being investigated (Dreesman et al., 1975; Shih and Gerin, 1975) . The relatively poor immunogenicity of these polypeptides and the difficulty of large scale purification may limit the applicability of this method. Currently, extensive efficacy and long-term safety tests in chimpanzees are under way for the 22-nm particle vaccine, as are detailed evaluations of the immune response-both humoral and cellular-to the new vaccine. A successful trial of the 22-nm (Voegt, 1942; MacCallum and Bradley, 1944; Findlay and Wilcox, 1945; Paul et al., 1945;  Neefe, Gellis and Stokes, 1946; Havens, 1945a Havens, , b, 1946 Krugman, Ward and Giles, 1962; Krugman, Giles and Hammond, 1967; Mascoli et al., 1973; Provost et al., 1973) . Although infectivity of blood and faeces was demonstrated in these pioneering studies, HAV was not cultivated from or identified in any of these specimens.
Hepatitis A antigen
Data and clinical specimens generated in early volunteer and marmoset studies, however, were instrumental to the ultimate visualization of a viruslike particle with hepatitis A antigen activity. In 1973, Feinstone et al. (1973) used immune electron microscopy to examine stool specimens taken from prison volunteers infected with the Willowbrook MS-1 strain of HAV. In these studies, Feinstone incubated convalescent serum from one of the volunteers with filtrates of acute phase stool specimens and detected aggregates and single 27-nm viruslike particles coated with antibody (Fig. 3) . The association of these particles, designated hepatitis A antigen (HA Ag), with HAV infection was supported by the failure to detect immune aggregates when preinoculation or convalescent stools were used as an antigen source or when acute phase stools were incubated wth pre-inoculation serum from patients with type A hepatitis or convalescent serum from patients with type B hepatitis or viral gastroenteritis. Furthermore, serological responses to HA Ag were demonstrated in paired serum samples of patients with experimental and natural type A hepatitis. FIG. 3 . Antibody-coated aggregate of hepatitis A antigen particles purified from the stools of a patient with acute type A hepatitis (2% phosphotungstic acid negative stain). The bar represents 100 nm.
Reports soon followed describing studies by Provost et al. (1975b) in which similar virus-like particles were observed in the sera and livers of Sanguinus mystax (marmosets) experimentally infected with the CR326 strain of HAV, which had been extensively characterized at the Merck Institute (Mascoli et al., 1973; Provost et al., 1973) . Since particles were observed by thin section electron microscopy within cytoplasmic vesicles, since buoyant density determinations and preliminary nucleic acid determinations were suggestive, Provost et al. (1975b) proposed that HAV is an RNA-containing enterovirus. The multiple densities for HA Ag detected by others, however (Feinstone et al., 1974; Bradley et al., 1975; Moritsugu et al., 1976) , and the heat stability of HAV are more characteristic of parvoviruses, small viruses containing single stranded DNA; additional characterization of HAV is needed before final classification of virus type can be made.
Identification of HA Ag particles in experimental infection of man and marmoset was confirmed by the detection of antigenically and morphologically indistinguishable particles in the stools of naturally infected humans (Gravelle et al., 1975; Locarnini et al., 1974; Dienstag et al., 1975c) and in the liver, bile and stool of experimentally infected chimpanzees (Schulman et al., 1976) , a species of non-human primates recently shown to be susceptible to HAV infection (Dienstag et al., 1975b Moritsugu et al. (1976) reported the successful use of stools from humans with naturally-acquired HAV infection as an HA Ag source for IAHA. Of the few techniques available today, IAHA has proved the most economical, simple, and widely used; however, it is still not commercially available. Another useful test, also limited to research laboratories, is a solid phase radioimmunoassay, which can be modified to detect both HA Ag and anti-HA (Hollinger et al., 1975; Purcell et al., 1976b (Dienstag et al., 1975a) . As Krugman observed in studies among children at the Willowbrook State School, faeces are infectious early during incubation and not much later than the initial appearance of jaundice (Krugman et al., 1962) . Antibody to HA Ag can be detected by immune electron microscopy or complement fixation during acute illness; however, the appearance of anti-HA cannot be detected for from 1 to 4 weeks after acute illness by IAHA. Subsequently anti-HA titres rise gradually and reach a peak, in man, about 2-3 months after acute illness. Although titres fall afterwards, relatively high titres may persist even 10 years after infection (Moritsugu et al., 1976; Gravelle et al., 1975; Locarnini et al., 1974; Dienstag et al., 1975c Dienstag et al., , 1975b Provost et al., 1975a; Miller et al., 1975; Krugman, Friedman and Lattimer, 1975; Dienstag, Alling and Purcell, 1976a) (Fig. 4) .
Epidemiology
Recently available serological techniques have been applied to investigate modes of HAV transmission and prevalence of HAV infection. Serological evidence for infection with HAV has been demonstrated in common-source water-borne (Feinstone et al., 1973; and foodborne outbreaks (Feinstone et al., 1973; Gravelle et al., 1975; Dienstag et al., 1975c; , shellfish-associated hepatitis (Dienstag et al., 1976c) , intra-family and intra-institutional outbreaks (Feinstone et al., 1973; , and nonhuman primate-associated hepatitis . A significant proportion of sporadic hepatitis has also been attributed serologically to HAV. On the other hand, although HAV can be transmitted experimentally by parenteral inoculation, type A hepatitis has not been confirmed serologically as a significant contribution to transfusion-associated hepatitis Knodell et al., 1975) , haemodialysis-associated hepatitis (Zuckerman, Courouce and Szmuness, unpublished data), drug abuse-related hepatitis (Mosley et al., 1977) , or other forms of percutaneous transmission via blood and , 292, 1141. 1975.) blood products. The rarity of percutaneous spread of HAV infection is consistent with the lack of a chronic HAV carrier state. Serological surveys have also confirmed epidemiological observations which suggest that frequency of exposure to HAV increases proportionally with age Szmuness et al., 1976; Villarejos et al., 1976) and inversely with rising socio-economic status (Miller et al., 1975; Szmuness et al., 1976; Villarejos et al., 1976 Knodell et al., 1975) . Cases of hepatitis which are serologically neither type A nor type B also occur among drug abusers (Mosley et al., 1977) , haemodialysis patients (Zuckerman and Courouce, unpublished data), intrafamily contacts , and intrainstitutional contacts (Ogra, unpublished data). Both cytomegalovirus and Epstein-Barr virus have also been excluded as the aetiological agent in most of these cases. Thus, the occurrence of what has been designated 'non-A, non-B' hepatitis suggests that one or more other hepatitis viruses exist. To date, however, no virus or virus antigen has been identified in these cases of human 'non-A, non-B' hepatitis.
